BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell killing across multiple tumor models, while BP-80 demonstrated good tolerability in primates and advanced tumor-targeted checkpoint inhibition. These findings support ongoing development of their cancer immunotherapy pipeline, including treatments for breast and prostate cancers.
BriaCell and BriaPro's immunotherapy data provide context for health sector activity on Pluang. For readers following health stocks, of 150 priced US health-sector stocks tradable on Pluang, 51 rose and 94 fell today. Notable movers include XRAY at USD 8.68 with a -13.97% change, TMDX at USD 77.21 with an 11.93% increase and 100% buy order activity, and BKD at USD 9.55 with an -11.66% change. These figures are as of Nov 06, 2026 20:42 WIB.
IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...
Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...
Guggenheim analyst Howard Ma raised JFrog's price target to $125, signaling a 67.5% potential upside from its current price of $74.62. JFrog reported strong Q3 2026 results with revenue up 31% year-over-year to $179.2 million, driven by a 60% surge i...
Iovance Biotherapeutics reported a strong Q3 with revenues up about 80% year-over-year and a gross margin of 60%. The company reaffirmed its 2026 revenue guidance of $410–$420 million and holds a solid cash reserve of $376 million, expected to last u...
Upstart Holdings has seen reduced loan originations and lowered its FY2026 guidance due to elevated default risks and higher funding costs. Despite these challenges, its fee-based revenue model and significant third-party funding help mitigate capita...
